{
    "clinical_study": {
        "@rank": "66988", 
        "arm_group": [
            {
                "arm_group_label": "MTX 12.5", 
                "arm_group_type": "Active Comparator", 
                "description": "Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab"
            }, 
            {
                "arm_group_label": "MTX 25 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab.  Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab"
            }
        ], 
        "brief_summary": {
            "textblock": "Assess the body's reaction to dose-response relationship for the adalimumab/Methotrexate\n      interaction in subjects with moderately to severely active ulcerative colitis."
        }, 
        "brief_title": "Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "Assess the Pharmacokinetic dose-response relationship for the adalimumab/Methotrexate\n      interaction in subjects with moderately to severely active UC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or non-pregnant, non-lactating females.   Females of child bearing potential\n             must have a negative serum pregnancy test prior to randomization, and must use a\n             hormonal (oral, implantable or injectable) or barrier method of birth control\n             throughout the study.  Females unable to bear children must have documentation of\n             such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal\n             [defined as a minimum of one year since the last menstrual period]).\n\n          -  Diagnosis of UC confirmed by established criteria, regardless of disease duration.\n\n          -  Moderate to severely active UC, defined by a modified Mayo Score \u22656, with confirmed\n             endoscopic activity by central reader (Mayo endoscopic subscore \u22652).\n\n          -  Require initiation with adalimumab for induction of remission.\n\n          -  Ability of subject to swallow study drug capsules.\n\n          -  Ability of subject to participate fully in all aspects of this clinical trial.\n\n          -  Written informed consent must be obtained and documented.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with a TNF antagonist or biological therapy.\n\n          -  Prior treatment with MTX.\n\n          -  Disease limited to the rectum (proctitis).\n\n          -  Documented presence of antibodies against adalimumab.\n\n          -  Contraindication for anti-TNF or MTX therapy.\n\n          -  Contraindication for endoscopy.\n\n          -  Ostomy.\n\n          -  Planned surgery."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716039", 
            "org_study_id": "RP1204"
        }, 
        "intervention": [
            {
                "arm_group_label": "MTX 12.5", 
                "description": "once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab.  Randomization will be stratified by disease activity (modified Mayo Score \u22649 or >9).\nSubjects will receive 18 weekly doses of MTX in addition to doses of adalimumab", 
                "intervention_name": "MTX 12.5", 
                "intervention_type": "Drug", 
                "other_name": "MTX"
            }, 
            {
                "arm_group_label": "MTX 25 mg", 
                "description": "once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab.  Randomization will be stratified by disease activity (modified Mayo Score \u22649 or >9).\nSubjects will receive 18 weekly doses of MTX in addition to doses of adalimumab", 
                "intervention_name": "MTX 25", 
                "intervention_type": "Drug", 
                "other_name": "MTX"
            }, 
            {
                "arm_group_label": [
                    "MTX 12.5", 
                    "MTX 25 mg", 
                    "Placebo"
                ], 
                "description": "Subjects will receive 18 weekly doses of adalimumab", 
                "intervention_name": "Adalimumab", 
                "intervention_type": "Drug", 
                "other_name": "Humira"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Moderately to severely active Ulcerative Colitis", 
        "lastchanged_date": "March 19, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination With Methotrexate for the Treatment of Patients With Ulcerative Colitis", 
        "overall_official": {
            "affiliation": "Robarts Research Institute - Western University", 
            "last_name": "Brian Feagan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PK parameters will include:\nMaximum plasma concentration (Cmax)\nTime to reach Cmax (Tmax)\nArea under the concentration time curve (AUC)\nElimination rate constant (k) Elimination half-life (t1/2)", 
            "measure": "Pharmacokinetic Analysis (PK) will measure antidrug antibodies (ADAs)and plasma concentrations of adalimumab and methotrexate.", 
            "safety_issue": "No", 
            "time_frame": "20 weeks"
        }, 
        "reference": [
            {
                "PMID": "16339095", 
                "citation": "Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76."
            }, 
            {
                "PMID": "22326435", 
                "citation": "Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W; EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012 May;142(5):1102-1111.e2. Epub 2012 Feb 8."
            }, 
            {
                "PMID": "21209123", 
                "citation": "Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780-7. Epub 2011 Jan 5."
            }, 
            {
                "PMID": "12584368", 
                "citation": "Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 Feb 13;348(7):601-8."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The primary efficacy outcome will be assessed by comparing the change in the modified Baron score from baseline to the final visit between the treatment groups", 
                "measure": "Clinical and Endoscopic Evaluation of the Efficacy of Combination Therapy", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }, 
            {
                "description": "To identify covariates (gender, weight, BMI, albumin, TNF, CRP, disease severity, concomitant medications) that might influence the clearance and or disposition of adalimumab", 
                "measure": "Identify covariates", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }, 
            {
                "description": "To evaluate the relationship between PK and efficacy (PD)", 
                "measure": "Relationship between PK and efficacy", 
                "safety_issue": "No", 
                "time_frame": "20 weeks"
            }
        ], 
        "source": "University of Western Ontario, Canada", 
        "sponsors": {
            "collaborator": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Western Ontario, Canada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}